| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
MRC Retrovirus Research Laboratory, Department of Veterinary Pathology, University of Glasgow, Glasgow G61 1QH, UK
Conclusion: Much progress has been made since the identification of Nef (or 3' orf as it was then known) as a protein product of HIV-1 in 1985 (Allan et al., 1985). As I have discussed in this review, a decade of studies has shown that Nef has a number of clearly defined in vitro biological functions and a critical role in virus pathogenesis in vivo. There are several tasks to be undertaken in the foreseeable future. Firstly, the biochemical mechanisms of Nef function in vitro must be accurately defined, hopefully leading to the development of chemotherapeutic antiviral agents. Implicit in this analysis must be the investigation of the influence of Nef on virus replication in cell types other than T cells that are known to be infected by HIV, e.g. macrophages and glial cells. It is conceivable that the biochemistry of Nef function in these cell types may be distinct from that in T cells. With regard to macrophages it is pertinent that Nef apparently interacts with a macrophage-specific tyrosine kinase, Hck, with high affinity (Saksela et al., 1995). Secondly, the relative contribution of each of the in vitro functions to the role of Nef in vivo must be identified. Intuitively, it is to be expected that both CD4 down-modulation and the enhancement of virus infectivity will be important for pathogenesis of HIV infection. However, formal proof of this must be obtained. It will also be important to ascertain whether these in vitro functions are truly independent. Although both CD4 down-modulation and enhancement of virus infectivity can occur independently under in vitro conditions, it cannot be ruled out that they are linked in some way in vivo. They may be manifestations of an underlying biochemical mechanism, as yet unidentified. The most obvious grey area concerning Nef function is the effect of Nef on signal transduction pathways. This aspect of Nef embraces the most controversy and disagreement and clear interpretation of the available data is impossible. Above all, the priority here must be to demonstrate that any effects of Nef observed in vitro are relevant to virus replication and not merely artifacts of expression of a heterologous protein. That is the real challenge for the future.
This article has been cited by other articles:
|
|
 |
|
  P. Vincent, E. Priceputu, D. Kay, K. Saksela, P. Jolicoeur, and Z. Hanna Activation of p21-activated Kinase 2 and Its Association with Nef Are Conserved in Murine Cells but Are Not Sufficient to Induce an AIDS-like Disease in CD4C/HIV Transgenic Mice J. Biol. Chem., March 17, 2006; 281(11): 6940 - 6954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-B. Huang, L. L. Jin, C. O. James, M. Khan, M. D. Powell, and V. C. Bond Characterization of Nef-CXCR4 Interactions Important for Apoptosis Induction J. Virol., October 15, 2004; 78(20): 11084 - 11096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Macdonald and M. Harris Hepatitis C virus NS5A: tales of a promiscuous protein J. Gen. Virol., September 1, 2004; 85(9): 2485 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Weng, E. Priceputu, P. Chrobak, J. Poudrier, D. G. Kay, Z. Hanna, T. W. Mak, and P. Jolicoeur CD4+ T Cells from CD4C/HIVNef Transgenic Mice Show Enhanced Activation In Vivo with Impaired Proliferation In Vitro but Are Dispensable for the Development of a Severe AIDS-Like Organ Disease J. Virol., May 15, 2004; 78(10): 5244 - 5257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Kay, P. Yue, Z. Hanna, S. Jothy, E. Tremblay, and P. Jolicoeur Cardiac Disease in Transgenic Mice Expressing Human Immunodeficiency Virus-1 Nef in Cells of the Immune System Am. J. Pathol., July 1, 2002; 161(1): 321 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Simard, P. Chrobak, D. G. Kay, Z. Hanna, S. Jothy, and P. Jolicoeur Expression of Simian Immunodeficiency Virus nef in Immune Cells of Transgenic Mice Leads to a Severe AIDS-Like Disease J. Virol., March 19, 2002; 76(8): 3981 - 3995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Khan, M. Garcia-Barrio, and M. D. Powell Restoration of Wild-Type Infectivity to Human Immunodeficiency Virus Type 1 Strains Lacking nef by Intravirion Reverse Transcription J. Virol., December 15, 2001; 75(24): 12081 - 12087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Hanna, X. Weng, D. G. Kay, J. Poudrier, C. Lowell, and P. Jolicoeur The Pathogenicity of Human Immunodeficiency Virus (HIV) Type 1 Nef in CD4C/HIV Transgenic Mice Is Abolished by Mutation of Its SH3-Binding Domain, and Disease Development Is Delayed in the Absence of Hck J. Virol., October 1, 2001; 75(19): 9378 - 9392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schaeffer, R. Geleziunas, and W. C. Greene Human Immunodeficiency Virus Type 1 Nef Functions at the Level of Virus Entry by Enhancing Cytoplasmic Delivery of Virions J. Virol., March 15, 2001; 75(6): 2993 - 3000. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. L. Caldwell, B. S. Egan, and V. L. Shepherd HIV-1 Tat Represses Transcription from the Mannose Receptor Promoter J. Immunol., December 15, 2000; 165(12): 7035 - 7041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Akari, S. Arold, T. Fukumori, T. Okazaki, K. Strebel, and A. Adachi Nef-Induced Major Histocompatibility Complex Class I Down-Regulation Is Functionally Dissociated from Its Virion Incorporation, Enhancement of Viral Infectivity, and CD4 Down-Regulation J. Virol., March 15, 2000; 74(6): 2907 - 2912. [Abstract] [Full Text]
|
|
|
|
|
|
M. Foti, L. Cartier, V. Piguet, D. P. Lew, J.-L. Carpentier, D. Trono, and K.-H. Krause The HIV Nef Protein Alters Ca2+ Signaling in Myelomonocytic Cells through SH3-mediated Protein-Protein Interactions J. Biol. Chem., December 3, 1999; 274(49): 34765 - 34772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Verhasselt, E. Naessens, C. Verhofstede, M. De Smedt, S. Schollen, T. Kerre, D. Vanhecke, and J. Plum Human Immunodeficiency Virus nef Gene Expression Affects Generation and Function of Human T Cells, But Not Dendritic Cells Blood, October 15, 1999; 94(8): 2809 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Calarota, A.-C. Leandersson, G. Bratt, J. Hinkula, D. M. Klinman, K. J. Weinhold, E. Sandstrom, and B. Wahren Immune Responses in Asymptomatic HIV-1-Infected Patients After HIV-DNA Immunization Followed by Highly Active Antiretroviral Treatment J. Immunol., August 15, 1999; 163(4): 2330 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Heyninck, D. De Valck, W. V. Berghe, W. Van Criekinge, R. Contreras, W. Fiers, G. Haegeman, and R. Beyaert The Zinc Finger Protein A20 Inhibits TNF-induced NF-kappa B-dependent Gene Expression by Interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-kappa B-inhibiting Protein ABIN J. Cell Biol., June 28, 1999; 145(7): 1471 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Welker, M. Harris, B. Cardel, and H.-G. Krausslich Virion Incorporation of Human Immunodeficiency Virus Type 1 Nef Is Mediated by a Bipartite Membrane-Targeting Signal: Analysis of Its Role in Enhancement of Viral Infectivity J. Virol., November 1, 1998; 72(11): 8833 - 8840. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
